Free Trial

OraSure Technologies Q3 2024 Earnings Report

OraSure Technologies logo
$3.43 -0.06 (-1.72%)
As of 03/28/2025 04:00 PM Eastern

OraSure Technologies EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.02
One Year Ago EPS
$0.27

OraSure Technologies Revenue Results

Actual Revenue
$39.92 million
Expected Revenue
$38.97 million
Beat/Miss
Beat by +$950.00 thousand
YoY Revenue Growth
-55.20%

OraSure Technologies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

OraSure Technologies Earnings Headlines

Trump's 100-Day Plan Triggers Global Retaliation
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
OraSure board authorizes $40M stock repurchase program
OraSure Announces $40 Million Stock Repurchase Program
See More OraSure Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OraSure Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OraSure Technologies and other key companies, straight to your email.

About OraSure Technologies

OraSure Technologies (NASDAQ:OSUR), together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

View OraSure Technologies Profile

More Earnings Resources from MarketBeat